| Mechanisms of drug induced QT interval prolongation ML Ponte, GA Keller, GD Girolamo Current drug safety 5 (1), 44-53, 2010 | 112 | 2010 |
| Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach B Oliveri, SR Mastaglia, GM Brito, M Seijo, GA Keller, J Somoza, RA Diez, ... European journal of clinical nutrition 69 (6), 697-702, 2015 | 66 | 2015 |
| Other drugs acting on nervous system associated with QT-interval prolongation GA Keller, ML Ponte, G Di Girolamo Current drug safety 5 (1), 105-111, 2010 | 65 | 2010 |
| Drug-induced QT interval prolongation in the intensive care unit CV Etchegoyen, GA Keller, S Mrad, S Cheng, G Di Girolamo Current clinical pharmacology 12 (4), 210-222, 2017 | 58 | 2017 |
| Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study G Di Girolamo, P Czerniuk, R Bertuola, GA Keller Clinical therapeutics 32 (1), 161-170, 2010 | 49 | 2010 |
| Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial M Cannellotto, M Duarte, G Keller, R Larrea, E Cunto, V Chediack, ... Emergency Medicine Journal 39 (2), 88-93, 2022 | 35 | 2022 |
| Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice G A Keller, P A Alvarez, M L Ponte, W H Belloso, C Bagnes, ... Current drug safety 11 (1), 86-98, 2016 | 35 | 2016 |
| Adverse drug reactions as a reason for admission to an internal medicine ward in Argentina PA Alvarez, F Bril, V Castro, I Meiville, CD Gonzalez, IG Centurion, ... International Journal of Risk & Safety in Medicine 25 (3), 185-192, 2013 | 35 | 2013 |
| Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide C González, V Beruto, G Keller, S Santoro, G Di Girolamo Expert opinion on investigational drugs 15 (8), 887-895, 2006 | 34 | 2006 |
| In vivo Phenotyping Methods: Cytochrome P450 Probes with Emphasis on the Cocktail Approach G Alberto Keller, M Laura Ferreirós Gago, R Alejandro Diez, ... Current Pharmaceutical Design 23 (14), 2035-2049, 2017 | 29 | 2017 |
| A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients F Bril, V Castro, I G Centurion, J Espinosa, G A Keller, C D Gonzalez, ... Current drug safety 11 (2), 156-163, 2016 | 28 | 2016 |
| Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study GA Keller, P Czerniuk, R Bertuola, JG Spatz, AR Assefi, G Di Girolamo Clinical therapeutics 33 (4), 500-510, 2011 | 23 | 2011 |
| Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose … G Di Girolamo, GA Keller, R Antonio, D Schere, CD Gonzalez Clinical therapeutics 30 (11), 2015-2023, 2008 | 20 | 2008 |
| Prokinetic agents and QT prolongation: a familiar scene with new actors GA Keller, G Di Girolamo Current drug safety 5 (1), 73-78, 2010 | 18 | 2010 |
| Tramadol induced QTc-Interval prolongation: prevalence, clinical factors and correlation to plasma concentrations G A Keller, M CV Etchegoyen, N Fernandez, N M Olivera, P N Quiroga, ... Current drug safety 11 (3), 206-214, 2016 | 17 | 2016 |
| Tramadol induced QTc-Interval prolongation: prevalence, clinical factors and correlation to plasma concentrations G A Keller, M CV Etchegoyen, N Fernandez, N M Olivera, P N Quiroga, ... Current drug safety 11 (3), 206-214, 2016 | 17 | 2016 |
| Relative bioavailability of new formulation of paracetamol effervescent powder containing sodium bicarbonate versus paracetamol tablets: a comparative pharmacokinetic study in … GD Girolamo, JAW Opezzo, MI Lopez, D Schere, G Keller, CD Gonzalez, ... Expert opinion on pharmacotherapy 8 (15), 2449-2457, 2007 | 16 | 2007 |
| Severe neutropenia in a renal transplant patient suggesting an interaction between mycophenolate and fenofibrate P Antonio Alvarez, J Egozcue, J Sleiman, L Moretti, G Di Girolamo, ... Current drug safety 7 (1), 24-29, 2012 | 14 | 2012 |
| Antihistamines: past answers and present questions GA Keller, G Di Girolamo Current drug safety 5 (1), 58-64, 2010 | 14 | 2010 |
| Meperidine-induced QTc-interval prolongation: prevalence, risk factors, and correlation to plasma drug and metabolite concentrations. GA Keller, EMC Villa, N Fernández, NM Olivera, PN Quiroga, RA Diez, ... International journal of clinical pharmacology and therapeutics, 2016 | 11 | 2016 |
Guillermo Di GirolamoSchool of Medicine, University of Buenos AiresDirección de correo verificada de fmed.uba.ar
